GlassScriptPhysician profile
Brett Jordan Capel
NPI 1710408000
$8,547.85
in general payments reported to CMS, 2019-2025
26 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.93 · 2022: $528 · 2023: $2,930 · 2024: $3,576 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,835 · Education: $155 · Consulting Fee: $16.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,835.25 |
| Education | $154.98 |
| Consulting Fee | $16.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,349.45 | 2022-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,074.59 | 2022-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $832.58 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Astrazeneca Pharmaceuticals LP | $675.57 | 2023-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $517.41 | 2019-2025 | |
| Ucb, INC. | $391.56 | 2022-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $351.07 | 2023-2024 | Taltz |
| Pfizer INC. | $329.16 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $275.27 | 2023-2025 | Idacio |
| Organon LLC | $163.70 | 2024-2025 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.28 | 2023-2024 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $73.26 | 2023-2024 | Orencia |
| Kiniksa Pharmaceuticals International, Plc | $67.66 | 2024 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $56.12 | 2023-2024 | Strensiq, Ultomiris |
| Radius Health, INC. | $38.75 | 2024 | Tymlos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $33.32 | 2024 | Ruconest |
| Sandoz INC. | $33.21 | 2024 | Hyrimoz |
| Genentech USA, INC. | $32.86 | 2024 | Actemra |
| Actelion Pharmaceuticals US, INC. | $24.58 | 2024 | Opsumit |
| Ani Pharmaceuticals, INC. | $22.30 | 2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals, LTD. | $21.40 | 2023 | Arcalyst |
| Sobi, INC | $19.27 | 2023 | |
| Alvogen INC | $18.06 | 2023 | Teriparatide |
| Adma Biomanufacturing LLC | $16.10 | 2023 | |
| Depuy Synthes Sales INC. | $14.17 | 2024 | Monovisc, Orthovisc |
| Alk-Abello, INC | $14.15 | 2023 | Odactra, Ragwitek, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Capel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.